Figure 1 from International Journal of General Medicine Dovepress Hepatitis C Treatment: Where Are We Now? | Semantic Scholar (2024)

Given the large number of chronic HCV carriers in China and other less developed countries solutions have to be found to produce DAAs most cost effectively, and analyzed in China, Europe and Australia.

Evaluated distribution of HCV genotypes among Syrian patients and in people who inject drugs found that less frequent genotypes such as 4 and 5 may become more frequent due to Syrian patients, and in the future genotype 3 may become an increasing problem due to the persons who injecting drugs.

This study model can expand the toolkit of HCV test-and-treat models to reach a broader population of marginalized communities—a critical next step to achieving national HCV elimination goals.

DAA therapy reduced fibrosis-4 scores and improved liver function, with significant reductions in aspartate transaminase, alanine aminotransferase, and total bilirubin levels, however, DAA therapy slightly increased uric acid, cholesterol, and low-density lipoprotein cholesterol levels.

Expanding DAA access was associated with a drop in HCV-related hospitalizations in the overall Canadian population coinciding with the 2014 policy change, and continued ongoing research examining the real-world effectiveness of DAAs is required.

While trends point to a potentially higher prevalence of HCV, it will require well-designed random surveys to obtain better estimates of the infection seroprevalence, supported by strong public health laboratory systems.

...

...

The aim of this review is to provide an update on the epidemiology of HCV infection across Europe, and to foster the discussion about eventual potential strategies to eradicate it.

Grazoprevir plus RBV was associated with a rapid and sustained suppression of HCV RNA and support further evaluation of grazoprevIR‐based regimens (NCT01716156; protocol P039).

In cirrhotic HCV GT1- or GT3-infected patients, ABT-493 plus ABt-530 with or without RBV achieved SVR12 rates of 96%-100% and was well tolerated.

Although HCV genotypes 1 and 3 infections are the most prevalent globally (67.0% if considered together), other genotypes are found more commonly in lower-income countries where still account for a significant proportion of HCV cases.

Eight weeks of treatment with the combination of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in most treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections, including those with compensated cirrhosis.

This review and debate will address the medical and legal issues involved in the purchase and importation of these medicines.

...

...